Cosmo Pharmaceuticals Nv · SIX:COPN
Cosmo Pharmaceuticals Nv — Investor Presentation (June 2021)
24 slides from Cosmo Pharmaceuticals Nv's investor presentation, June 2021
Slide 1: Corporate Presentation
Corporate Presentation June 2021 Cosmo Pharmaceuticals Corporate Presentation June 2021
Slide 2: Safe Harbour
SAFE HARBOUR This presentation may include forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. The inclusion of forward-looking statements should not be regarded as a representation by Cosmo that any of its p
Slide 3: Overview
Overview Cosmo Pharmaceuticals 3 Corporate Presentation June 2021
Slide 4: Cosmo Overview
COSMO OVERVIEW Two marketed medtech Three marketed Market Cap1 products therapeutics CHF 1,308.3 million GI Genius™ Lialda® /Mezavant® Net Cash1 Uceris®/Cortiment® €207.9 million Aemcolo®/RelaFalk® One approved therapeutic (EU) Rich development pipeline 1 as at 31 May 2021 Cosmo Pharmaceuticals 4 Co
Slide 5: Cosmo's Own Products Development Pipeline
COSMO’S OWN PRODUCTS DEVELOPMENT PIPELINE PRODUCT INDICATION PH I PH II PH III Aemcolo® IBS-D Acute Uncomplicated Diverticulitis* Small Intestine BacteriaI Overgrowth (SIBO)* Minimal Hepatic Encephalopathy* Byfavo™ Procedural Sedation APPROVED Lesion detection during Methylene Blue MMX® colonoscopy
Slide 6: Cosmo's Stakes in Other Companies as a Result of Partnerships and Spin-offs
COSMO’S STAKES IN OTHER COMPANIES AS A RESULT OF PARTNERSHIPS AND SPIN-OFFS • As at 31st of May 2021 the market value of our stakes in other companies, cash, loans, investments and treasury shares was €614.0 million. €M 31 May 2021 Shareholding in Cassiopea 223.3 Shareholding in Acacia Pharma Group
Slide 7: Financial Highlights 2020
FINANCIAL HIGHLIGHTS 2020 Revenue Operating profit Cash, bonds and fund €60.9m €6.9m investments 2019: €62.5m 2019: Operating Loss €12.3m €212.9m 2019: €268.2m Manufacturing of own products and related services Loss after tax €32.8m €7.9m Equity stakes in other 2019: €28.7m 2019: Loss after tax €24.
Slide 8: Commercialisation Through Partnerships
COMMERCIALISATION THOUGH PARTNERSHIPS Cosmo Pharmaceuticals 8 Corporate Presentation June 2021
Slide 9: Commercialisation Through Partnerships
COMMERCIALISATION THOUGH PARTNERSHIPS Cosmo Pharmaceuticals 9 Corporate Presentation June 2021
Slide 10: Recent Milestones
Recent Milestones Cosmo Pharmaceuticals 10 Corporate Presentation June 2021
Slide 11: Recent Milestones
RECENT MILESTONES • FDA approval of GI Genius™, April 2021 • EU rights (plus Switzerland, UK, EEA countries, Russia and Mexico) for Lumeblue™ (Methylene Blue MMX®) licensed to Alfasigma S.p.A., February 2021 • Successful outcome of Rifamycin 600mg phase II trial in IBS-D announced, January 2021 • Li
Slide 12: Products Update
Products Update Cosmo Pharmaceuticals 12 Corporate Presentation June 2021
Slide 13: Products Update: GI Genius
PRODUCTS UPDATE GI Genius™ • In April 2021, GI Genius™ was approved by the FDA. • The FDA assessed the safety and effectiveness of the GI Genius through a multicenter, prospective, randomized, controlled study in Italy with 700 subjects 40-80 years old who were undergoing a colonoscopy for colorecta
Slide 14: GI Genius - The Global AI Partnership with Medtronic
PRODUCTS UPDATE GI Genius™ - The global AI partnership with Medtronic • Now Approved in the US, Europe, Australia, Israel and the United Arab Emirates • Extensive marketing campaign by Medtronic underway • https://www.medtronic.com/us-en/c/digestive-gastrointestinal/gi-genius.html Cosmo Pharmaceutic
Slide 15: Products Update: GI Genius
PRODUCTS UPDATE GI Genius™ Cosmo Pharmaceuticals 15 Corporate Presentation June 2021
Slide 16: Products Update: GI Genius
PRODUCTS UPDATE GI Genius™ • In April 2021, GI Genius™ was launched by Medtronic in the US • The US market has approximately 32,000 endoscopy towers and GI Genius™ is compatible with all makes • The device is initially being marketed through an agreement lasting 3 years and providing for yearly subs
Slide 17: Products Update: Methylene Blue MMX
PRODUCTS UPDATE Methylene Blue MMX® • In August 2020, the European Commission approved Methylene Blue MMX® for the visualization of colorectal lesions during colonoscopies • In December 2020, we licensed the Chinese rights for Lumeblue™ to China Medical System Holdings Ltd. (“CMS”) (SEHK: 867) • In
Slide 18: Products Update: Aemcolo
PRODUCTS UPDATE Aemcolo™ • In January 2021, we announced the successful outcome of our Phase II Proof of Concept (POC) clinical trial of Rifamycin-MMX 600mg in Irritable Bowel Syndrome with Diarrhea (IBS-D). Together with our licensees, we will immediately commence discussions with the U.S. and EU r
Slide 19: 2021 Key Priorities & Outlook
2021 Key Priorities & Outlook Cosmo Pharmaceuticals 19 Corporate Presentation June 2021
Slide 20: Key Priorities for 2021
KEY PRIORITIES FOR 2021 • Help Medtronic to maximise GI Genius™ sales • Finalize Cassiopea’s strategic deal to launch Winlevi® • Commence the Methylene Blue MMX® confirmatory phase III trial required for US approval • Together with our licensees RedHill and Dr. Falk, commence discussions with the US
Slide 21: 2021 Guidance
2021 GUIDANCE • The coronavirus pandemic will likely continue to impact Aemcolo™ and Eleview® sales and delay our clinical trials • Guidance is based on obtaining FDA approval for GI Genius™ in H1 2021 and assumes an increase in costs associated with the deployment of GI Genius machines to Medtronic
Slide 22: Cosmo as Seen by Equity Analysts
COSMO AS SEEN BY EQUITY ANALYSTS • Analyst – Peter Welford • Analyst – Barbora Blaha • BUY Rating • OUTPERFORM Rating • 12 month price target CHF 120 • 12 month price target CHF 95 • Analyst – Paul Verbraeken • Analyst – Bob Pooler • BUY Rating • Risk Adjusted NPV per share CHF 134 • 12 month price
Slide 23: Thank You
Thank You Cosmo Pharmaceuticals 23 Corporate Presentation June 2021
Slide 24: Cosmo Pharmaceuticals NV Contact Details
Cosmo Pharmaceuticals NV Riverside II Sir John Rogerson’s Quay Dublin 2, Ireland media@cosmopharma.com Mr. Alessandro Della Cha, CEO adellacha@cosmopharma.com Mr. Niall Donnelly, CFO ndonnelly@cosmopharma.com Cosmo Pharmaceuticals 24 Corporate Presentation June 2021
Cosmo Pharmaceuticals — Investor Presentation (June 2021) on 6ix